PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Multiple myeloma (MM) is a heterogeneous plasma cell malignancy with variable patient outcomes.
• Accurate risk stratification is crucial for tailoring MM treatment regimens.
• Currently, a validated immunohistochemical marker for predicting MM prognosis is lacking.

Purpose of the Study:

• To investigate the prognostic value of proteolipid protein 2 (PLP2) in newly diagnosed multiple myeloma (NDMM) patients.
• To assess the correlation between PLP2 expression and clinicopathological features in MM.
• To determine if PLP2 can serve as a predictive biomarker for MM prognosis and treatment response.

Main Methods:

• Immunohistochemistry (IHC) was employed to evaluate PLP2 expression.
• Bone marrow (BM) biopsy specimens from 87 NDMM patients were analyzed.
• Statistical analyses were performed to correlate PLP2 levels with clinical and pathological data.

Main Results:

• PLP2 expression was significantly elevated in high-risk MM patients.
• Increased PLP2 levels correlated with disease progression and poorer prognosis.
• PLP2 expression paralleled elevated levels of beta-2 microglobulin (β2-MG) and lactate dehydrogenase (LDH).
• Patients with lower PLP2 expression demonstrated a more favorable response to treatment.

Conclusions:

• Proteolipid protein 2 (PLP2) emerges as a potential novel biomarker for prognostic prediction in MM.
• PLP2 expression levels may guide therapeutic strategies and identify patients needing intensive treatment.
• PLP2 represents a potential therapeutic target for developing new anti-MM treatments.